Navigation Links
China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results
Date:11/9/2010

China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010... -- TAI'AN, Shandong, China, Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals Click to view news release full screen  

China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results

 

TAI'AN, Shandong, China, Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that it will host a conference call at 9:00 a.m. EST on Tuesday, November 16, 2010, to discuss the third quarter 2010 financial results.  

Hosting the call will be Mr. Colin Zhao, Chief Executive Officer, and Mr. Tristan Kuo, Chief Financial Officer. The Company plans to distribute its earnings press release prior to the call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 877-409-5468. International callers should dial +1-702-894-2400. The pass code for the call is 23890623.

If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Tuesday, November 16, 2010 at 11:00 a.m. EST. To access the replay, dial 800-642-1687, international callers should dial +1-706-645-9291. The conference pass code is 23890623.

About China Biologic Products, Inc.China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.Company Contact:Investor Relations Contact:Mr. Ming Yin

Mr. Crocker Coulson, President Vice President - Finance

CCG Investor RelationsChina Biologic Products, Inc.

Phone: +1-646-213-1915Tel: +86-851-3605846

Email: crocker.coulson@ccgir.comEmail: IR@chinabiologic.com

www.ccgirasia.comwww.chinabiologic.com
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. China Medicine Announces Strong Second Quarter 2008 Results
7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
8. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
9. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. China Biologic Products Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 23, 2017 China Biologic Products, Inc. (NASDAQ: ... plasma-based biopharmaceutical company in China, today announced its financial results ... Fourth Quarter 2016 Financial Highlights ... by 21.7% in RMB terms, or increased by 13.6% in ... same quarter of 2015. Gross profit increased ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... Services portfolio to include an array of biochemical analyses critical for Lead ... to drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism ...
(Date:2/23/2017)... 23, 2017  Imanis Life Sciences announced today ... oncolytic vaccinia viruses for virotherapy research. These viruses ... Genelux,s proprietary, vaccinia virus-based technology platform for research ... into a partnership with Genelux to offer researchers, ... for use in research," said Dr. Kah ...
(Date:2/23/2017)... Winston-Salem, NC (PRWEB) , ... February 23, 2017 , ... ... pleased to announce a new partnership with Compass Research . GGI's mission is ... gifting a vaccine to a child in need in honor of each clinical trial ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):